Loading
A phase 3 trial of Trastuzumab rezetecan, Docetaxel, Trastuzumab in her2-positive breast cancer, run by Jiangsu HengRui Medicine Co., Ltd., active and no longer recruiting.
A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer is a phase 3 interventional study registered as NCT07196774 by Jiangsu HengRui Medicine Co., Ltd., with 740 participants enrolled, started 2025-10-23 and due to reach its primary completion in 2027-12. Interventions recorded: SHR-A1811 for Injection, Docetaxel injection, Trastuzumab Injection, Carboplatin for Injection, Pertuzumab Injection. Conditions listed: Early-stage or Locally Advanced HER2-positive Breast Cancer. No results are recorded here; the registry entry is the source.
Shares Trastuzumab rezetecan, Pertuzumab, Jiangsu Hengrui Pharmaceuticals, Trastuzumab.
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Pertuzumab, Trastuzumab, Docetaxel, HER2-positive breast cancer.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Trastuzumab, Topoisomerase-I inhibitors (and ADC payloads).
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Topoisomerase-I inhibitors (and ADC payloads), HER2-positive breast cancer.
Shares Trastuzumab rezetecan, Pertuzumab, Jiangsu Hengrui Pharmaceuticals, Trastuzumab.
Shares Trastuzumab rezetecan, Jiangsu Hengrui Pharmaceuticals, Docetaxel, Topoisomerase-I inhibitors (and ADC payloads).